A surrogate end point is often used to evaluate the effects of treatments or exposures on the true end point in medical researches. Various criteria for the statistical surrogate, principal surrogate and strong surrogate have been proposed. We first illustrate that, with a surrogate end point that is defined by these criteria, it is possible that a treatment has a positive effect on the surrogate, which in turn has a positive effect on the true end point, but the treatment has a negative effect on the true end point. We define such a phenomenon as a surrogate paradox. The surrogate paradox also means that the sign of the treatment effect on the true end point is unpredictable by the effect signs of both the treatment on the surrogate and th...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
Summary. Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate e...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
When a treatment has a positive average causal effect (ACE) on an intermediate variable or surrogate...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Randomized Phase II or Phase III clinical trials that are powered based on clinical endpoints, such ...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Surrogate endpoints: wishful thinking or reality? Generally, before a new drug can be accepted for t...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
In this paper, we show that Prentice's criteria for surrogates can be strengthened to remedy so...
In clinical research, a clinical endpoint is a sign or symptom that constitutes a target outcome of ...
Background: In recent years the use of surrogate end points (S) has become an interesting issue. In ...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
Summary. Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate e...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
Summary. We define a surrogate end point as a measure or indicator of a biological process that is o...
When a treatment has a positive average causal effect (ACE) on an intermediate variable or surrogate...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Randomized Phase II or Phase III clinical trials that are powered based on clinical endpoints, such ...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Surrogate endpoints: wishful thinking or reality? Generally, before a new drug can be accepted for t...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
In this paper, we show that Prentice's criteria for surrogates can be strengthened to remedy so...
In clinical research, a clinical endpoint is a sign or symptom that constitutes a target outcome of ...
Background: In recent years the use of surrogate end points (S) has become an interesting issue. In ...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
Summary. Frangakis and Rubin (2002, Biometrics 58, 21–29) proposed a new definition of a surrogate e...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...